Indications

Pre-Clinical

IND-Enabling

Phase 1/2

Phase 3

GBM

PDAC

Refractory Melanoma

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Baylor College of MedicinePhase 1, NCT04157127

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.
Multi-site<br /> Phase 2, NCT06805305

Glioblastoma

Multi-site
Phase 2, NCT06805305

This is a randomized, prospective, multi-center, open-label study to evaluate the safety and efficacy of the DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care (SOC) on the overall survival of adult patients with newly diagnosed Glioblastoma (GBM) compared to SOC alone.
MD Anderson<br /> Phase 1, Pending

Sarcoma

MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.